We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Matthew
Beasley
matthew.beasley@nhs.net
Matthew
Beasley
matthew.beasley@nhs.net
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Liver cancer is a growing problem. Deaths from liver cancer have increased by 80% over the last 10 years. Radiotherapy can be used to treat liver cancer, but it can also hurt healthy cells near the cancer too. This is because the liver moves as you breathe, and it can be hard to tell the difference between cancer cells and healthy cells nearby. We often need to lower the dose of radiation we want to use to treat the cancer because we might hurt the healthy cells near the cancer.
The aim of this study is to improve the visualisation of healthy and unhealthy tissues by reducing motion and improving contrast between organs by asking participants to drink tea or fruit juice and holding their breath during an MRI scan.
Patients in work package 1, will be interviewed to explore their views and current experience of liver cancer radiotherapy. They will be asked about different ways of holding their breath and drinking fluids before their MRI scan (known as oral contrasts) that they might otherwise buy in the shops.
In work package 2, different oral contrasts and ways of holding their breath will be compared in fifteen healthy volunteers who will each have four MRI scans.
Patients from the patient and public involvement group will have input in the study by helping to review the results from work package 2 and help agree the methods to test in work package 3. Work package 3 will study 15 patients who are having radiotherapy to treat their liver cancer. In addition to the MRI scan received as part of their standard of care radiotherapy planning pathway, the 15 participants will have an extra MRI scan to compare the use of the chosen oral contrast and breath hold with their standard of care MRI scan. This will be to find out if doctors can see normal tissues and cancer better which might lead to more precise liver radiotherapy treatments.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Radiotherapy;Imaging;
You can take part if:
You may not be able to take part if:
Work package 1 (qualitative interviews with patients having SABR to treat primary or secondary liver cancer): • Inability to participate in discussions about their treatment experience. Work package 2 (efficacy evaluation of oral contrast and breathing management in healthy volunteers): • Any contraindication to magnetic resonance imaging (1.5 Tesla) in line with the LTHT local rules and SOP. • Any contraindication to the candidate oral contrasts. • Any contraindication antispasmodics. Work package 3 (effectiveness evaluation of oral contrast and breathing management in liver SABR patients): • Any contraindication to magnetic resonance imaging (1.5 Tesla) in line with the LTHT local rules and SOP. • Any contraindication to the candidate oral contrasts. • Any contraindication to antispasmodics (if used as part of the patient's standard of care).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by LEEDS TEACHING HOSPITALS NHS TRUST and funded by NIHR Academy .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 55694
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
